Considering these issues, we chose the transient combination of the IGF-1R inhibitor with osimertinib, demonstrating a favorable efficacy and safety in the CDXs and PDX models of AXL-low-expressing EGFR-mutated lung cancer. This evidence concerns the gene IGF1R and lung cancer.